Hormonal
Roux-en-Y gastric bypass (RYGB) achieves superior and durable weight loss compared to purely restrictive procedures (like VBG or AGB) primarily through hormonal mechanisms—specifically the suppression of ghrelin and enhancement of incretins (GLP-1, PYY)—rather than gastric restriction or malabsorption alone.
If you are considering Roux-en-Y gastric bypass, understand that its success relies less on the small stomach pouch size and more on hormonal changes. The surgery suppresses the hunger hormone ghrelin and increases satiety hormones like GLP-1 and PYY. This hormonal shift reduces appetite and improves glucose tolerance, often before significant weight loss occurs. This distinguishes it from purely restrictive surgeries which often fail long-term because they do not alter these hormonal signals.
In our opinion, RYGB is more effective than VBG primarily because of the profound loss of appetite that typically results from RYGB but is less consistent after VBG... This decrease in hunger is not explained by early satiety from gastric restriction alone... The two mechanisms cited most often to explain the greater efficacy of RYGB over VBG are malabsorption and dumping syndrome... clinically significant malabsorption... is not observed after the standard proximal RYGB.
Why this rating
The paper is a review of multiple prospective studies, human data, and animal models, though it notes heterogeneity in ghrelin data.
Source
Gastric Bypass for Obesity: Mechanisms of Weight Loss and Diabetes Resolution
David E. Cummings et al. · The Journal of Clinical Endocrinology & Metabolism · 2004
DOI 10.1210/jc.2004-0433
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →